← Back to Search

Other

Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity (RAISE Trial)

Phase 2
Waitlist Available
Research Sponsored by Saol Therapeutics Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time of study drug administration to end of study visit (day 168)

Summary

This trial is testing a new treatment called SL-1002 to help people with muscle stiffness in their arms or legs. The study will include 32 patients who will receive the treatment. Researchers want to see if SL-1002 can safely reduce muscle stiffness and improve flexibility.

Eligible Conditions
  • Spasticity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time of study drug administration to end of study visit (day 168)
This trial's timeline: 3 weeks for screening, Varies for treatment, and time of study drug administration to end of study visit (day 168) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Occurrence of treatment emergent adverse events (TEAEs) overall

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: SL-1002Experimental Treatment1 Intervention
SL-1002 injectable solution, single dose
Group II: Matching placeboPlacebo Group1 Intervention
Matching placebo injectable solution, single dose

Find a Location

Who is running the clinical trial?

Saol Therapeutics IncLead Sponsor
2 Previous Clinical Trials
166 Total Patients Enrolled
~9 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top